SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

KPTI

Karyopharm Therapeutics Inc.
NASDAQHealth Care

Latest close: 0.39 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◆Adverse 8-K filing●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Oct 1, 2026Reported sale · Form 4Kristin Abate, Chief Accounting Officer · $449.8Open the filing ↗
  3. Sep 18, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record1,07119 flagged findings
Reported transactions (Form 4)73since May 24, 2023 · and 1 other holding
Corporate events (8-K)30since May 25, 2023

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-14share offering or dilution eventrecentOpen filing ↗
    “…value at the end of each reporting period, with changes in fair value recognized as a component of other income, net on our…”
    +1 more passage from the same document
    • “…recognized as a component of other income, net on our condensed consolidated statements of operations. See Note 10, “ Long-Term…”
  • 2026-05-14listing compliance noticerecentOpen filing ↗
    “…our common stock and would adversely affect our ability to raise additional capital or to enter into strategic transactions. Any…”
    +1 more passage from the same document
    • “…controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome…”
  • 2026-05-14export control restrictionsrecentOpen filing ↗
    “…and finished product candidate used in our and our collaborators’ preclinical studies and clinical trials, particularly with respect…”
  • 2026-05-14capital return (buybacks/dividends)recentOpen filing ↗
    “…maturity divided by the market price per share of our common shares on the redemption date. The number of shares of common stock…”
    +1 more passage from the same document
    • “…make-whole adjustment in the conversion rate in connection with such corporate event. However, in no event can the conversion rate…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:15 on Feb 26, 2025) · 1:15 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 1,071)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 14, 268-K ↗Current report · Other events new
  • Oct 8, 26SCHEDULE 13G/A ↗Passive stake · Anders Hove · 4.5% · event on Oct 2, 26 · amendment
  • Oct 2, 26Form 4 ↗Insider transaction
  • Sep 25, 26SCHEDULE 13G/A ↗Passive stake · Anders Hove · 5.7% · event on Sep 22, 26 · amendment
  • Sep 25, 26SCHEDULE 13G/A ↗Passive stake · Anders Hove · 5.7% · event on Sep 22, 26 · amendment
  • Sep 18, 268-K ↗Current report · Change in shareholder rights · Bylaws or fiscal year change
  • Sep 11, 268-K ↗Current report · A debt obligation was accelerated
  • Sep 4, 26SCHEDULE 13G ↗Passive stake · Integrated Core Strategies (US) LLC · 5.7% · event on Aug 31, 26
  • Sep 2, 26Form 4 ↗Insider transaction
  • Aug 31, 268-K ↗Current report · Other events
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · RA Capital Management, L.P. · 9.9% · event on Jun 30, 26 · amendment
  • Aug 13, 2610-Q ↗Quarterly report
  • Aug 13, 268-K ↗Current report · Results
  • Aug 12, 26SCHEDULE 13G/A ↗Passive stake · Adage Capital Management, L.P. · 6.8% · event on Jun 30, 26 · amendment
  • Aug 11, 26SCHEDULE 13G/A ↗Passive stake · THE GOLDMAN SACHS GROUP, INC. · 6.3% · event on Jun 30, 26 · amendment
  • Jul 31, 268-K ↗Current report · Other events
  • Jul 30, 26Form 4 ↗Insider transaction
  • Jul 28, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.6% · event on Jun 30, 26
  • Jul 17, 268-K ↗Current report · A senior executive left or was appointed
  • Jun 5, 26SCHEDULE 13G/A ↗Passive stake · T. Rowe Price Investment Management, Inc. · 6.6% · event on May 31, 26 · amendment
  • May 28, 268-K ↗Current report · A senior executive left or was appointed
  • Insider transaction · 3 Form 4 filingsshow all 3hide

1,071 filings on record, the oldest from Nov 5, 13.

Listing the 25 most recent filings of the 1,071 on record.

8-Ks, explained

Stress3Structure37Governance46
  • Sep 11, 26StressA debt obligation was accelerated+4 more in the same filing8-K 2.04 ↗
  • Jul 17, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • May 28, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Mar 24, 26StructureSold unregistered shares+4 more in the same filing8-K 3.02 ↗
  • Mar 3, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Oct 14, 25StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Oct 8, 25StructureSold unregistered shares+7 more in the same filing8-K 3.02 ↗
  • Governance5 senior executive changes2024 – 2025show all 5hide
    • Sep 11, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • May 29, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jan 31, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jan 2, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Nov 20, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Nov 8, 24StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Sep 17, 24StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Aug 29, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • May 31, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗

5 older filings not shown · The record reaches back to Dec 11, 13.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

The full record holds 3 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • RA Capital Management, L.P.9.9%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Affinity Asset Advisors, LLC8.6%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Adage Capital Management, L.P.6.8%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • T. Rowe Price Investment Management, Inc.6.6%May 31, 26SCHEDULE 13G/A ↗
  • THE GOLDMAN SACHS GROUP, INC.6.3%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
show 5 more holdershide
  • Integrated Core Strategies (US) LLC5.7%Aug 31, 26SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.5.6%Jun 30, 26SCHEDULE 13G ↗
  • Anders Hove4.5%Oct 2, 26SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
  • Opaleye Management Inc.2.7%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Millennium Management LLC2.3%Mar 31, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 1, 26Sell$450Kristin AbateChief Accounting Officer↗
  • Sep 1, 26Sell$38Kristin AbateChief Accounting Officer↗
  • Jul 28, 26Sell$1KStuart PoultonEVP, Chief Development Officer↗
  • May 14, 26Sell$3KMichael ManoEVP, CLO&Secretary↗
  • May 14, 26Sell$21KRichard A. PaulsonPresident and CEO↗
  • May 14, 26Sell$504Kristin AbateChief Accounting Officer↗
  • May 14, 26Sell$3KSohanya Roshan ChengEVP & Chief Commercial Officer↗
  • May 14, 26Sell$4KReshma RangwalaEVP & Chief Medical Officer↗
  • May 14, 26Sell$4KStuart PoultonEVP, Chief Development Officer↗
  • Apr 21, 26Sell$4KReshma RangwalaEVP & Chief Medical Officer↗
  • Mar 2, 26Sell$116KRichard A. PaulsonPresident and CEO↗
  • Mar 2, 26Sell$48KReshma RangwalaEVP & Chief Medical Officer↗

There are 8 more transactions in this stretch.

Stock compensation, tax and giftsshow the 20 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • May 21, 26Compensationamount n/aGAREN G BOHLIN↗
  • May 21, 26Compensationamount n/aDEEPIKA PAKIANATHAN↗
  • May 21, 26Compensationamount n/aBarry E Greene↗
  • May 21, 26Compensationamount n/aChen Schor↗
  • May 21, 26Compensationamount n/aChristy J. Oliger↗
  • May 21, 26Compensationamount n/aZhen Su↗
  • May 13, 26Compensationamount n/aMichael ManoEVP, CLO&Secretary↗
  • May 13, 26Compensationamount n/aRichard A. PaulsonPresident and CEO↗
  • May 13, 26Compensationamount n/aKristin AbateChief Accounting Officer↗
  • May 13, 26Compensationamount n/aSohanya Roshan ChengEVP & Chief Commercial Officer↗
  • May 13, 26Compensationamount n/aReshma RangwalaEVP & Chief Medical Officer↗
  • May 13, 26Compensationamount n/aStuart PoultonEVP, Chief Development Officer↗
  • Feb 5, 26Compensationamount n/aRichard A. PaulsonPresident and CEO↗
  • Jan 31, 26Compensationamount n/aStuart PoultonEVP, Chief Development Officer↗
  • Jan 31, 26Compensationamount n/aMichael ManoEVP, CLO&Secretary↗
  • Jan 31, 26Compensationamount n/aLori MacomberEVP, CFO & Treasurer↗
  • Jan 31, 26Compensationamount n/aReshma RangwalaEVP & Chief Medical Officer↗
  • Jan 31, 26Compensationamount n/aSohanya Roshan ChengEVP & Chief Commercial Officer↗
  • Jan 27, 26Compensationamount n/aKristin AbateChief Accounting Officer↗
  • Oct 15, 25Compensationamount n/aLori MacomberEVP, CFO & Treasurer↗

The full record holds 181 transactions and goes back to Jan 4, 23.

Its sector and its market

Karyopharm Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Karyopharm Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Karyopharm Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
1,071 documents on file, from Nov 5, 2013 to Oct 14, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.